Latest News | Competition Comm Clears Kotak-Biocon Biologics Deal

New Delhi, Aug 11 (PTI) Fair trade regulator CCI has cleared Kotak Special Situations Fund's (KSSF) proposed investment in Biocon Biologics Ltd under the green channel route.

In February, KSSF, an arm of Kotak Mahindra Bank, announced a Rs 1,070 crore investment in Biocon to help a subsidiary of the Bengaluru-based company in an acquisition.

Also Read | UPSC NDA 2 Admit Card 2023 Out on upsc.gov.in, Know How to Download.

The investment will help Biocon Biologics' acquisition of the biosimilars business of its partner Viatris.

KSSF is a Sebi-registered alternative investment fund (AIF).

Also Read | Delhi Gas Leak Incident: 24 Students of MCD School Hospitalised After Gas Leakage in Naraina.

The combination relates to the acquirer (KSSF) proposing to purchase certain equity shares in the target (Biocon Biologics).

Biocon Biologics is a biosimilars company which is engaged in the manufacture and commercialisation of pharmaceutical formulations.

The Competition Commission of India (CCI) said it has approved the deal.

"The parties' activities do not exhibit any horizontal, vertical, or complementary overlaps in any of the plausible relevant markets.

"Therefore, the proposed combination is being notified under the green channel," according to an update on CCI's website on Thursday.

Under the green channel route, a transaction which does not raise any risk of an appreciable adverse effect on competition is deemed to be approved on being intimated to the anti-trust regulator.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)